硝羟喹啉对耳念珠菌临床分离株的体外抗菌活性
本研究评估硝羟喹啉对35株来自五个不同分支的耳念珠菌临床分离株的体外活性。微量肉汤稀释法显示硝羟喹啉MIC范围为0.125-1 mg/L(MIC50/90为0.25/0.5 mg/L),活性优于氟康唑、阿尼芬净和两性霉素B。纸片扩散法与MIC相关性良好(Pearson r=-0.74),提示硝羟喹啉可能成为耳念珠菌尿路感染的治疗选择。
要点
- 硝羟喹啉对耳念珠菌临床分离株体外活性优异,MIC 0.125-1 mg/L。
- 与氟康唑、阿尼芬净和两性霉素B相比,硝羟喹啉体外活性更高。
- 硝羟喹啉口服后尿中浓度高,可能用于耳念珠菌尿路感染。
核心结论
- 硝羟喹啉对耳念珠菌临床分离株具有优异的体外活性,MIC范围为0.125-1 mg/L。
- 硝羟喹啉是已批准且耐受性良好的抗菌药物,口服后尿中浓度高,可能成为耳念珠菌尿路感染的治疗选择。
研究设计与样本
- 研究纳入35株耳念珠菌临床分离株,来源多样,代表全部五个不同分支。
- 采用微量肉汤稀释法评估硝羟喹啉活性,并在RPMI-1640和Müller-Hinton琼脂平板上进行纸片扩散法药敏试验。
- 同时测定氟康唑、伏立康唑、两性霉素B和阿尼芬净的最低抑菌浓度。
主要发现
- 硝羟喹啉MIC范围为0.125-1 mg/L,MIC50/90为0.25/0.5 mg/L。
- 两性霉素B在4/35株中MIC >1 mg/L,阿尼芬净在26/35株中MIC >0.06 mg/L,氟康唑在31/35株中MIC >4 mg/L。
- 分支I分离株的硝羟喹啉MIC略低(范围0.125-0.5 mg/L,平均MIC 0.375 mg/L),分支III为(范围0.5-1 mg/L,平均MIC 0.7 mg/L;p=0.0094)。
- 使用RPMI琼脂进行纸片扩散法时,MIC与抑菌圈相关性良好,Pearson相关系数为-0.74(95% CI -0.86至-0.54)。
关键数值与推荐
- 硝羟喹啉对耳念珠菌的MIC范围为0.125-1 mg/L。
- 作为对比,EUCAST关于大肠埃希菌非复杂性尿路感染的折点为≤16 mg/L。
临床怎么用
- 硝羟喹啉可能作为耳念珠菌尿路感染(candiduria)的治疗选择,因其口服后尿中浓度高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the in vitro activity of nitroxoline against a molecularly characterized collection of clinical Candida auris isolates. METHODS: Thirty-five clinical isolates of C. auris from diverse sources representing all five different C. auris clades were included in the study. Nitroxoline activity was assessed using broth microdilution. Additionally, susceptibility testing by disc diffusion was assessed on RPMI-1640 and Müller-Hinton agar plates. Minimal inhibitory concentrations of the antifungals fluconazole, voriconazole, amphotericin B and anidulafungin were determined. RESULTS: Nitroxoline MICs ranged from 0.125 to 1 mg/L (MIC50/90 0.25/0.5 mg/L). Compared with amphotericin B (MIC >1 mg/L in 4/35 isolates), anidulafungin (MIC >0.06 mg/L in 26/35 isolates) and fluconazole (MIC >4 mg/L in 31/35 isolates), in vitro activity of nitroxoline was high. Isolates belonging to clade I had marginally lower nitroxoline MICs (range 0.125-0.5 mg/L, mean MIC 0.375 mg/L) compared with clade III (range 0.5-1 mg/L, mean MIC 0.7 mg/L; p = 0.0094). The correlation of MIC and inhibition zones by disc diffusion was good when using RPMI-agar for disc diffusion, with a Pearson's correlation coefficient of -0.74 (95% CI -0.86 to -0.54). CONCLUSIONS: Nitroxoline has excellent in vitro activity against C. auris isolates, with MICs of 0.125-1 mg/L (for comparison, the EUCAST breakpoint for uncomplicated urinary tract infection with Escherichia coli is ≤ 16 mg/L). It is an approved, well-tolerated antimicrobial that achieves high urinary concentrations after oral administration and could be a useful treatment option in C. auris candiduria.
引用
- Fuchs F, Hof H, Hofmann S, et al. Antifungal activity of nitroxoline against Candida auris isolates. Clin Microbiol Infect. 2021. PMID: 34245904. doi:10.1016/j.cmi.2021.06.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。